Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Substance abuser" patented technology

Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the substance in amounts or with methods which are harmful to themselves or others, and is a form of substance-related disorder.

Systems and methods for trigger risk, substance use, and / or undesirable behavior detection

The present disclosure generally relates to systems and methods for trigger risk, substance use, and / or undesirable behavior detection. In exemplary embodiments, a system is configured to be operable for identifying trigger risk(s), undesirable and / or desirable behavior(s) and / or substance (ab)use and / or addictive activity(ies) of one or more entity(ies) and determining and implementing action(s) or pre-empting and / or mitigating undesirable behavior(s) and / or encouraging and / or facilitating desirable behavior(s). The system comprises a plurality of digital and / or physical constructs and / or engines operable for providing various capabilities. The system is configured to be operable for providing a plurality of data from sensor(s), sensor array(s), device(s), system(s), and / or network(s) to the plurality of digital and / or physical constructs and / or engines.
Owner:CONQUER YOUR ADDICTION LLC

Cannabichromene derivatives and use thereof

The present invention comprises a series of CBC derivative compounds and a method for their use. The compounds may be used to treat and / or diagnose cancer, Parkinson's Disease, Alzheimer's Disease, schizophrenia, depression, anxiety, substance abuse disorders, pain, and / or other diseases and disorders. The compounds may exist as a pharmaceutically acceptable salt or a stereoisomer thereof.
Owner:REMEDY PROCESSORS LLC

Neuroactive steroids, compositions, and uses thereof

PendingUS20260116912A1Organic active ingredientsNervous disorderWithdrawal syndromeSubstance abuser
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS INC

Methods and compositions for inhibiting glyoxalase 1 (GLO1)

Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.
Owner:PALMER ABRAHAM +2

Use of phytocannabinoids and their analogs as negative allosteric modulators of the CB1 receptor

In one aspect, the disclosure relates to the use of negative allosteric modulators (NAMs) of cannabinoid receptor 1 (CB1) and pharmaceutical compositions comprising the same in methods of treating or preventing diseases or disorders including substance abuse, anxiety, pain, obesity, cancers, neurodegenerative disorders, and central nervous system (CNS) disorders. In one aspect, the NAM can be selected from H4-CBD or CBDP. In some aspects, the pharmaceutical compositions additionally include Δ9-tetrahydrocannabinol (THC), and the NAMs of CB1 reduce or eliminate unwanted neurological side effects of THC while preserving its disease- and symptom-mitigating effects.
Owner:UNIVERSITY OF MISSISSIPPI +1

Neuroactive steroids, compositions, and uses thereof

InactiveUS20260116911A1Organic active ingredientsNervous disorderWithdrawal syndromeSubstance abuser
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS INC

Quinoline derivatives that act as kappa opioid receptor antagonists

Disclosed herein are kappa opioid receptor (KOR) antagonist compounds of formula (I) and formula (II) and their pharmaceutically acceptable salts, as well as pharmaceutical compositions thereof. The compounds are useful in methods for treating a variety of diseases and disorders for which KOR antagonism is indicated, including substance abuse disorders, depression, anxiety, and other psychiatric conditions. TIFF2026506965000204.tif34128
Owner:THE SCRIPPS RES INST

Squaramide derivatives as CB1 allosteric modulators

Squaramide-based cannabinoid 1 receptor (CB1R) allosteric modulators are described. Exemplary analogs may provide improved potency and pharmacokinetic properties. Methods of treating diseases mediated by CB1R, such as substance abuse and obesity, using the analogs are described.
Owner:RES TRIANGLE INST

Method for treating psychiatric disorders and dementia or mild cognitive impairment via intermittent memantine- and amantadine-based dosing regimen and drug combinations

PCT designated stageWO2026107197A2Amine active ingredientsDosing regimenLumateperone
Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.
Owner:THERACAST INC

Combination of mitragynine and naltrexone for substance use disorders

A combination therapy for use in treatment of substance abuse disorders, including alcohol use disorder (AUD) and opioid use disorder (OUD), includes both mitragynine (MG) and naltrexone (NTX). NTX is understood to be a mu opioid antagonist that is expected to block MG's analgesic effects. However, combining MG and NTX therefore results in a unique, unexpected, and beneficial treatment that decreases alcohol self-administration to a greater extent than either alone.
Owner:UNIV HOUSTON SYST

Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives

The invention relates to cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]-decan-2-one derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse / dependence.
Owner:GRUNENTHAL GMBH

Piperidinyl pain-sensitive peptide receptor compounds

The present invention provides novel piperidinyl-containing pain-sensitive peptide receptor ligand compounds and pharmaceutical compositions that are useful in the treatment of neurological diseases and disorders wherein such ligands address the negative effects of such disorders. Such neurological diseases and conditions include acute and chronic pain, substance abuse / dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, kidney disease, cardiovascular disease, and Parkinson's disease.
Owner:ASTRAEA THERAPEUTICS LLC

Derivatives of ureas as allosteric modulators of CB1

To provide a method for treating a disease mediated by cannabinoid 1 receptor (CB1R).SOLUTION: Heteroaryl and aliphatic analogs of diarylurea-based CB1R allosteric modulators of Formula (I) are provided. Exemplary analogs can provide improved potency and pharmacokinetic properties. Also provided are methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and adiposity.SELECTED DRAWING: None
Owner:RES TRIANGLE INST

Cannabichromene Derivatives And Use Thereof

The present invention comprises a series of CBC derivative compounds and a method for their use. The compounds may be used to treat and / or diagnose cancer, Parkinson's Disease, Alzheimer's Disease, schizophrenia, depression, anxiety, substance abuse disorders, pain, and / or other diseases and disorders. The compounds may exist as a pharmaceutically acceptable salt or a stereoisomer thereof.
Owner:REMEDY PROCESSORS LLC

Intranasal neuropeptides for use in stress-related impairments

Intranasal neuropeptide Y (NPY) analogs having D-amino acids, such as [D26-His]-NPY are provided for early intervention to prevent or to treat, to reverse, or reduce symptoms of stress-related impairments such as PTSD, depression, substance abuse, and / or memory deficits following exposure to traumatic or surgical stress.
Owner:NEW YORK MEDICAL COLLEGE

2-bromo-lysergic acid diethylamide for substance abuse

A method of treating substance abuses in an individual, by administering a first dose of 2-bromo-lysergic acid diethylamide (BOL-148) to an individual, producing an additive effect by administering a second dose of BOL-148 to the individual, and reducing use of the substance.
Owner:CERUVIA LIFESCIENCES LLC

Composition and method for in vivo assay of opioid receptors

Compositions and methods are provided to determine occupancy level of opioid receptors in a subject. The disclosed methods may be performed non-invasively in the inner ear of the subject, and may be performed at a point-of-care location to provide guidance to a practitioner on tapering on pharmacotherapy or on a patient's risk of relapse for substance abuse.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE

Quinoline derivatives which act as kappa-opioid receptor antagonists

Disclosed herein are kappa-opioid receptor (KOR) antagonist compounds of Formula (I), Formula (II), and their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds are useful in methods of treatment of various diseases and disorders for which KOR antagonism is indicated, including substance abuse disorders, depression, anxiety, and other psychiatric conditions.
Owner:THE SCRIPPS RES INST

Methods and Compositions for Use of a Chemokine Receptor Antagonist Peptide to Treat Addiction, Substance Abuse Disorders or Symptoms Thereof

A method of treating a person with a substance abuse disorder, in particular, opioid abuse and psychostimulant abuse with a chemokine receptor antagonist pharmaceutical composition, is provided herein. An antagonist comprising five contiguous amino acids having the general structure: A-B-C-D-E in which A is Ser, Thr, Asn, Glu, or Ile; B is Ser, Thr, Asp, or Asn; C is Thr, Ser, Asn, Arg, or Trp; D is Tyr and E is Thr, Ser, Arg, or Gly, is provided herein. The stereoisomeric amino acids are D stereoisomers. The method both relieves a person's symptoms and reduces the person's risks of addiction.
Owner:CREATIVE BIO PEPTIDES INC

Sublingual substance abuse disorder and Anti-addiction lozenge

Formulations and methods are described to produce sublingual substance abuse disorder and anti-addiction lozenges. The lozenges may include troche base, ketamine, and buprenorphine. The lozenges may include 0.25 weight percent to 2.53 weight percent ketamine and 0.61 weight percent to 4.88 weight percent buprenorphine. The methods may include placing troche base into a chamber and applying heat to the chamber to melt the troche base. The methods may include adding a first ingredient into the chamber and mixing the first ingredient into the melted troche base. The first ingredient may include ketamine. The methods may include adding a second ingredient into the chamber and mixing the second ingredient into the melted troche base with the first ingredient. The second ingredient may include buprenorphine. The methods may include pouring the melted mixture into a mold. The methods may include cooling the melted mixture in the mold to form the lozenge.
Owner:SYNERGISTIC THERAPEUTICS LLC

Edge-intelligent IoT-based wearable device for detection of cravings in individuals

A wearable physiological monitoring system comprises commercially available off-the shelf components. With the growth of interrelated systems of computing devices, mechanical and digital machines, objects, animals or people connected by the Internet, there is a significant interest in the use of wearable sensors such as cell watches, and smart phones. These wearable sensors may be used to monitor physiological signals and provide health information. An edge-intelligent Internet based wearable assists in substance-abuse detection by monitoring and interpreting an individual's physiological signals on continuous basis. The wearable device helps in monitoring cravings and substance abuse of the individual and help the healthcare provider to start an early intervention as required. The proposed system is developed as a dedicated substance abuse wearable system. An example of a wearable device is a medical quality wearable which yielded a correlation of 0.89 for accelerometer measurements and 0.92 for average heart rate measurements in tests.
Owner:REINHARDT MEGAN +1